High Content Screening Market Size, Share, Industry Trends and Forecast to 2030

Market Size & CAGR of High Content Screening Market in 2021

The global high content screening market was valued at USD 1.45 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 7.8% during the forecast period from 2021 to 2028. The increasing adoption of high content screening techniques in drug discovery and development, along with advancements in imaging technologies, are driving the growth of the market.

COVID-19 Impact on the High Content Screening Market

The COVID-19 pandemic has posed both challenges and opportunities for the high content screening market. While the pandemic led to disruptions in supply chains and clinical trials, it also highlighted the importance of high content screening in drug discovery and development. The increased focus on finding effective treatments and vaccines for COVID-19 has further accelerated the adoption of high content screening technologies.

High Content Screening Dynamics

The high content screening market is driven by factors such as the rising prevalence of chronic diseases, increasing investments in R&D by pharmaceutical and biotechnology companies, and technological advancements in imaging and analysis software. Additionally, the shift towards personalized medicine and the need for more efficient drug discovery processes are propelling the growth of the market.

Segments and Related Analysis

By Technology:

- Cell Imaging and Analysis Systems - Flow Cytometry - High Content Analysis Informatics - Consumables - Services

By Application:

- Target Identification and Validation - Primary and Secondary Screening - Toxicity Studies - Compound Profiling - Others

By Region Analysis

North America

- The North American high content screening market is expected to dominate the global market, driven by the presence of key players, technological advancements, and high healthcare expenditure in the region.

Europe

- The European market is witnessing significant growth in high content screening, fueled by collaborations between research institutions and pharmaceutical companies, as well as favorable government initiatives supporting R&D.

Asia Pacific

- The Asia Pacific region is projected to experience rapid growth in the high content screening market due to the increasing healthcare infrastructure, rising investments in life sciences research, and expanding pharmaceutical industry.

Key Market Players and Competitive Landscape

Some of the key players in the global high content screening market include Thermo Fisher Scientific Inc., PerkinElmer Inc., General Electric Company, Becton Dickinson and Company, and Merck KGaA. These companies are focused on strategic collaborations, product launches, and technological advancements to strengthen their market position.

Recent Happenings in the High Content Screening Market

- In January 2021, Thermo Fisher Scientific launched the new CellInsight CX7 LZR High-Content Analysis Platform, designed to accelerate drug discovery and cell biology research. - In March 2021, PerkinElmer announced the acquisition of Nexcelom Bioscience, a provider of automated cell counting and analysis solutions, to enhance its high content screening capabilities. - In August 2021, GE Healthcare unveiled the IN Carta High Content Analysis System, featuring advanced imaging and analysis tools for drug discovery and cell biology applications.